Citicoline and COVID-19: vis-à-vis conjectured

16Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Coronavirus disease 2019 (COVID-19) is a current pandemic disease caused by a novel severe acute respiratory syndrome coronavirus virus respiratory type 2 (SARS-CoV-2). SARS-CoV-2 infection is linked with various neurological manifestations due to cytokine-induced disruption of the blood brain barrier (BBB), neuroinflammation, and peripheral neuronal injury, or due to direct SARS-CoV-2 neurotropism. Of note, many repurposed agents were included in different therapeutic protocols in the management of COVID-19. These agents did not produce an effective therapeutic eradication of SARS-CoV-2, and continuing searching for novel anti-SARS-CoV-2 agents is a type of challenge nowadays. Therefore, this study aimed to review the potential anti-inflammatory and antioxidant effects of citicoline in the management of COVID-19.

Cite

CITATION STYLE

APA

Al-kuraishy, H. M., Al-Buhadily, A. K., Al-Gareeb, A. I., Alorabi, M., Hadi Al-Harcan, N. A., El-Bouseary, M. M., & Batiha, G. E. S. (2022, December 1). Citicoline and COVID-19: vis-à-vis conjectured. Naunyn-Schmiedeberg’s Archives of Pharmacology. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00210-022-02284-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free